Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors
July 08 2019 - 4:05PM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of
tumor drug resistance, today announced the appointment of Susan L.
Kelley, M.D. to its Board of Directors. Dr. Kelley will serve as an
independent director and member of the Compensation Committee.
“It is a pleasure to welcome Susan to the Board of Directors at
such an exciting time for Deciphera,” said Steve Hoerter, President
and Chief Executive Officer of Deciphera. “I look forward to
leveraging her vast experience across the spectrum of oncology drug
development as we continue to advance the ripretinib program and
the rest of our pipeline, including DCC-3014, rebastinib and our
recently announced potential first-in-class ULK kinase inhibitor,
DCC-3116.”
“With its first Phase 3 data readout on the horizon, the coming
months will be an important time for Deciphera,” said Dr. Kelley.
“I look forward to collaborating with the highly accomplished Board
and management team to realize the full potential of its pipeline
derived through its novel switch control inhibitor platform.”
Dr. Kelley brings to Deciphera over 25 years of experience
across all stages of oncology drug research and development. Most
recently she served as Chief Medical Officer of the Multiple
Myeloma Research Consortium (MMRC) where she led the strategic
design and management of clinical trials conducted by leading
myeloma clinical research centers in North America. Prior to the
MMRC, she held positions of increasing responsibility at Bayer
Healthcare Pharmaceuticals and Bayer-Schering Pharma, including
Vice President, Global Clinical Development and Therapeutic Area
Head – Oncology, where she led the team responsible for the
development and worldwide regulatory approval of Nexavar®
(sorafenib). Prior to joining Bayer, Dr. Kelley worked at
Bristol-Myers Squibb in Oncology and Immunology drug development,
ultimately serving as Executive Director, Oncology Clinical
Research, at the Bristol-Myers Squibb Pharmaceutical Research
Institute. She currently serves as a member of the Board of
Directors at multiple publicly traded companies including VBL
Therapeutics, Daré Bioscience, Inc., and ArQule, Inc. Dr. Kelley
received her M.D. from Duke University School of Medicine. She was
a Fellow in Medical Oncology and Clinical Fellow in Medicine at
Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow
in Medical Oncology and Pharmacology at Yale University School of
Medicine, where she also served as a Clinical Assistant Professor
of Medicine.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals (NASDAQ: DCPH) is a clinical-stage
biopharmaceutical company focused on improving the lives of cancer
patients by tackling key mechanisms of drug resistance that limit
the rate and/or durability of response to existing cancer
therapies. Our small molecule drug candidates are directed against
an important family of enzymes called kinases, known to be directly
involved in the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, such
as macrophages. We have used our platform to develop a diverse
pipeline of tumor-targeted and immuno-targeted drug candidates
designed to improve outcomes for patients with cancer by improving
the quality, rate and/or durability of their responses to
treatment.
Availability of Other Information About Deciphera
Pharmaceuticals
Investors and others should note that Deciphera Pharmaceuticals
communicates with its investors and the public using its company
website (www.deciphera.com), including but not limited to investor
presentations and scientific presentations, Securities and Exchange
Commission filings, press releases, public conference calls and
webcasts. The information that Deciphera Pharmaceuticals posts on
these channels and websites could be deemed to be material
information. As a result, Deciphera Pharmaceuticals encourages
investors, the media and others interested in Deciphera
Pharmaceuticals to review the information that it posts on these
channels, including Deciphera Pharmaceuticals’ investor relations
website, on a regular basis. This list of channels may be updated
from time to time on Deciphera Pharmaceuticals' investor relations
website and may include other social media channels than the ones
described above. The contents of Deciphera Pharmaceuticals' website
or these channels, or any other website that may be accessed from
its website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding our expectations regarding timing of reporting top-line
data from our INVICTUS pivotal Phase 3 study, the potential for
ripretinib (DCC-2618) and our other drug candidates (DCC-3116,
rebastinib and DCC-3014) based on our kinase switch control
inhibitor platform to provide clinical benefit and treat cancers
such as GIST and other possible indications, preparations for a
possible NDA, pending positive study results, and commercial launch
of ripretinib in fourth-line and fourth-line plus GIST, if
approved. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the delay of any
current or planned clinical studies or the development of our drug
candidates, including ripretinib, rebastinib, , DCC-3014 and
DCC-3116, our advancement of multiple early-stage and later-stage
efforts, our ability to successfully demonstrate the efficacy and
safety of our drug candidates including in later-stage studies, the
preclinical and clinical results for our drug candidates, which may
not support further development of such drug candidates, our
efforts to scale up and manage drug product manufacturing, our
ability to implement commercial readiness, actions of regulatory
agencies, any or all of which may affect the initiation, timing and
progress of clinical studies and other risks identified in our SEC
filings, including our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2019, and subsequent filings with the SEC.
We caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. We
disclaim any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190708005706/en/
Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com 781-906-1112
Media: Gina Nugent, The Yates Network
gina@theyatesnetwork.com 617-460-3579
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024